摘要
耐碳青霉烯类肠杆菌科细菌感染正成为临床重大挑战,这类感染缺乏疗效肯定的治疗药物,患者病死率极高,探索治疗这类细菌感染的策略刻不容缓。迄今为止,有关研究主要基于新药研究与开发、既有抗菌药物的重新评价和抗菌药物联合使用等。替加环素在我国临床可供使用,但临床效果存疑;多黏菌素具有较好的体外抗菌活性,但临床用药方案尚未确立;碳青霉烯类联合其他药物的优化治疗方案也正在探索之中;碳青霉烯酶抑制剂复方还未在我国上市。与此同时,控制碳青霉烯类耐药肠杆菌科细菌感染流行也属当务之急。
ObjectiveCarbapenem resistant Enterobacteriaceae infections is becoming a major challenge to clinicians,which resulted in extremely high mortality owing to the limited antibiotics option.It is urgently to explore strategies to manage such bacterial infections.So far,the research is mainly focused on the research and development of new drugs,as well as the re evaluation of classic antimicrobial drugs and the combined treatment regimens.Tigecycline is available in our country,but the clinical effect is still doubtful.Polymyxin has a good effect on drug sensitivity test in vitro,but the clinical dosing has not been established.Carbapenems combining with other drugs as optimizing treatment program is also being explored.Carbapenemase inhibitor combination has not yet listed on Chinese market.In the mean time,it is urgent to prevent and to control carbapenem resistant Enterobacteriaceae bacterial infection.
作者
肖婷婷
肖永红
XIAO Tingting;XIAO Yonghong(State Key Laboratory for Diagnosis and Treatment of Infectious Disease,the First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou 310003,China;Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,Hangzhou 310003,China)
出处
《医药导报》
CAS
北大核心
2018年第1期1-5,共5页
Herald of Medicine
基金
浙江省重大科技专项重大社会发展项目(2015C03032)
关键词
碳青霉烯类
耐药
肠杆菌科细菌
感染
治疗策略
Carbapenem
Resistant
Enterobacteriaceae
Infection
Treatment strategies
